Advertisement

Clinical Oral Investigations

, Volume 23, Issue 1, pp 361–367 | Cite as

Survivin expression in head and neck squamous cell carcinomas is frequent and correlates with clinical parameters and treatment outcomes

  • Adrian MünscherEmail author
  • Sebastian Prochnow
  • Amit Gulati
  • Guido Sauter
  • Balazs Lörincz
  • Marco Blessmann
  • Henning Hanken
  • Arne Böttcher
  • Till Sebastian Clauditz
Original Article
  • 141 Downloads

Abstract

Objectives

Strong expression of survivin is associated with worse survival in many different tumours, and in cell culture, a correlation between radiation resistance and survivin expression can be seen. The potential of survivin expression as a prognostic/predictive marker or therapeutic target has not been examined in head and neck squamous cell carcinomas (HNSCC) yet.

Material and methods

Retrospective study of 452 tissue samples and clinical data from patients with squamous cell carcinomas of the larynx/hypopharynx (LSCC), oral cavity (OSCC) and oropharynx (OPSCC) treated in the University Medical Centre Hamburg-Eppendorf between 2002 and 2006. The expression patterns were detected by tissue microarray technique and correlated with clinical parameters (sex, age, tumour location, TNM 7th edition, grading, recurrence-free and overall survival).

Results

222 OSCC, 126 OPSCC and 105 LSCC tumours of 118 females and 335 males with a mean follow-up of 41.3 months were examined. Survivin expression correlates with pN, cM, pT and overall survival.

Conclusion and clinical relevance

The potential of survivin as a prognostic/predictive marker is very high. The findings have to be confirmed in a larger cohort of HNSCC esp. in those tumours treated primarily with radio/radiochemotherapy.

Keywords

Survivin Prognosis Head and neck squamous cell carcinoma (HNSCC) 

Notes

Funding

The work was supported by the Institute of Pathology and the Department of Otolaryngology, Head and Neck Surgery at the University Medical Centre Hamburg-Eppendorf.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all participants included in the study.

References

  1. 1.
    Hunter KD, Parkinson EK, Harrison PR (2005) Profiling early head and neck cancer. Nat Rev Cancer 5(2):127–135CrossRefGoogle Scholar
  2. 2.
    Parkin DM, Lӓӓrӓ E, Muir CS (1988) Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer 41(2):184–197CrossRefGoogle Scholar
  3. 3.
    Ragin CC, Modugno F, Gollin SM (2007) The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus. J Dent Res 86(2):104–114CrossRefGoogle Scholar
  4. 4.
    Sharma H, Sen S, Mathur M, Bahadur S, Singh N (2004) Combined evaluation of expression of telomerase, survivin, and anti-apoptotic Bcl-2 family members in relation to loss of differentiation and apoptosis in human head and neck cancers. Head Neck 26(8):733–740CrossRefGoogle Scholar
  5. 5.
    Pickhard A, Grӧber S, Haug AK et al (2014) Survivin and pAkt as potential prognostic markers in squamous cell carcinoma of the head and neck. Oral Surg Oral Med Oral Pathol Oral Radiol 117(6):733–742CrossRefGoogle Scholar
  6. 6.
    Farnebo L, Tiefenbӧck K, Ansell A, Thunell LK, Garvin S, Roberg K (2013) Strong expression of survivin is associated with positive response to radiotherapy and improved overall survival in head and neck squamous cell carcinoma patients. Int J Cancer 133(8):1994–2003CrossRefGoogle Scholar
  7. 7.
    Lippert BM, Knauer SK, Fetz V, Mann W, Stauber RH (2007) Dynamic survivin in head and neck cancer: molecular mechanism and therapeutic potential. Int J Cancer 121(6):1169–1174CrossRefGoogle Scholar
  8. 8.
    Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3(8):917–921CrossRefGoogle Scholar
  9. 9.
    Marioni G, D’Alessandro E, Bertolin A, Staffieri A (2010) Survivin multifaceted activity in head and neck carcinoma: current evidence and future therapeutic challenges. Acta Otolaryngol 130(1):4–9CrossRefGoogle Scholar
  10. 10.
    Scheper MA, Nikitakis NG, Sauk JJ (2007) Survivin is a downstream target and effector of sulindac-sensitive oncogenic Stat3 signalling in head and neck cancer. Int J Oral Maxillofac Surg 36(7):632–639CrossRefGoogle Scholar
  11. 11.
    Cui M, Au JL, Wientjes MG, O’Donnell MA, Loughlin KR, Lu Z (2015) Intravenous siRNA silencing of survivin enhances activity of mitomycin C in human bladder RT4 xenografts. J Urol 194(1):230–237CrossRefGoogle Scholar
  12. 12.
    Gibbons JA, Kanwar JR, Kanwar RK (2015) Iron-free and iron-saturated bovine lactoferrin inhibit survivin expression and differentially modulate apoptosis in breast cancer. BMC Cancer 15:425CrossRefGoogle Scholar
  13. 13.
    Adamkov M, Výbohová D, Tupá V, Chylíková J, Horáček J, Benčat M (2015) Expression and significance of survivin in colorectal high grade and low grade adenomas. Acta Histochem 117(6):590–594CrossRefGoogle Scholar
  14. 14.
    Phatak P, Byrnes KA, Mansour D, Liu L, Cao S, Li R, Rao JN, Turner DJ, Wang JY, Donahue JM (2016) Overexpression of miR-214-3p in esophageal squamous cancer cells enhances sensitivity to cisplatin by targeting survivin directly and indirectly through CUG-BP1. Oncogene 35(16):2087–2097CrossRefGoogle Scholar
  15. 15.
    Lu CD, Altieri DC, Tanigawa N (1998) Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 58(9):1808–1812Google Scholar
  16. 16.
    Ezponda T, Pajares MJ, Agorreta J, Echeveste JI, Lopez-Picazo JM, Torre W, Pio R, Montuenga LM (2010) The oncoprotein SF2/ASF promotes non-small cell lung cancer survival by enhancing survivin expression. Clin Cancer Res 16(16):4113–4125CrossRefGoogle Scholar
  17. 17.
    Yip KW, Shi W, Pintilie M, Martin JD, Mocanu JD, Wong D, MacMillan C, Gullane P, O’Sullivan B, Bastianutto C, Liu FF (2006) Prognostic significance of the Epstein-Barr virus, p53, Bcl-2, and survivin in nasopharyngeal cancer. Clin Cancer Res 12(19):5726–5732CrossRefGoogle Scholar
  18. 18.
    Yi XP, Han T, Li YX, Long XY, Li WZ (2015) Simultaneous silencing of XIAP and survivin causes partial mesenchymal-epithelial transition of human pancreatic cancer cells via the PTEN/PI3K/Akt pathway. Mol Med Rep 12(1):601–608CrossRefGoogle Scholar
  19. 19.
    Cavalieri F, Beretta GL, Cui J, Braunger JA, Yan Y, Richardson JJ, Tinelli S, Folini M, Zaffaroni N, Caruso F (2015) Redox-sensitive PEG-polypeptide nanoporous particles for survivin silencing in prostate cancer cells. Biomacromolecules 16(7):2168–2178CrossRefGoogle Scholar
  20. 20.
    Lin CK, Chao TK, Yu CP, Yu MH, Jin JS (2009) The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters. APMIS 117(3):162–175CrossRefGoogle Scholar
  21. 21.
    Krambeck AE, Dong H, Thompson RH, Kuntz SM, Lohse CM, Leibovich BC, Blute ML, Sebo TJ, Cheville JC, Parker AS, Kwon ED (2007) Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. Clin Cancer Res 13(6):1749–1756CrossRefGoogle Scholar
  22. 22.
    Labarrade F, Bergeron L, Serre C, Lebleu A, Busuttil V, Botto JM, Domloge N (2015) Modulating the expression of survivin and other basal epidermal proteins protects human skin from UVB damage and oxidative stress. J Cosmet Dermatol 14(3):191–203CrossRefGoogle Scholar
  23. 23.
    Fukuda S, Pelus LM (2006) Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 5(5):1087–1098CrossRefGoogle Scholar
  24. 24.
    Yamamoto T, Manome Y, Nakamura M, Tanigawa N (2002) Downregulation of survivin expression by induction of the effector cell protease receptor-1 reduces tumor growth potential and results in an increased sensitivity to anticancer agents in human colon cancer. Eur J Cancer 38(17):2316–2324CrossRefGoogle Scholar
  25. 25.
    Khan Z, Khan N, Tiwari RP, Patro IK, Prasad GB, Bisen PS (2010) Down-regulation of survivin by oxaliplatin diminishes radioresistance of head and neck squamous carcinoma cells. Radiother Oncol 96(2):267–273CrossRefGoogle Scholar
  26. 26.
    Khan Z, Tiwari RP, Mulherkar R, Sah NK, Prasad GBKS, Shrivastava BR, Bisen PS (2009) Detection of survivin and p53 in human oral cancer: correlation with clinicopathologic findings. Head Neck 31(8):1039–1048CrossRefGoogle Scholar
  27. 27.
    Mita AC, Mita MM, Nawrocki ST, Giles FJ (2008) Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 14(16):5000–5005CrossRefGoogle Scholar
  28. 28.
    Jaiswal PK, Goel A, Mittal RD (2015) Survivin: a molecular biomarker in cancer. Indian J Med Res 141(4):389–397CrossRefGoogle Scholar
  29. 29.
    Waligórska-Stachura J, Jankowska A, Waśko R, Liebert W, Biczysko M, Czarnywojtek A, Baszko-Błaszyk D, Shimek V, Ruchała M (2012) Survivin—prognostic tumor biomarker in human neoplasms—review. Ginekol Pol 83(7):537–540Google Scholar
  30. 30.
    Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC, Willi N, Mihatsch MJ, Sauter G, Kallioniemi OP (1999) Survey of gene amplifications during prostate cancer progression by high-throughput fluorescence in situ hybridization on tissue microarrays. Cancer Res 59(4):803–806Google Scholar
  31. 31.
    Warnakulasuriya S (2009) Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 45(4–5):309–316CrossRefGoogle Scholar
  32. 32.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90CrossRefGoogle Scholar
  33. 33.
    Thomas GR, Nadiminti H, Regalado J (2005) Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. Int J Exp Pathol 86(6):347–363CrossRefGoogle Scholar
  34. 34.
    Funk GF, Karnell LH, Robinson RA, Zhen WK, Trask DK, Hoffman HT (2002) Presentation, treatment, and outcome of oral cavity cancer: a National Cancer Data Base report. Head Neck 24(2):165–180CrossRefGoogle Scholar
  35. 35.
    Marioni G, Bertolin A, Giacomelli L, Marchese-Ragona R, Savastano M, Calgaro N, Marino F, de Filippis C, Staffieri A (2006) Expression of the apoptosis inhibitor protein survivin in primary laryngeal carcinoma and cervical lymph node metastasis. Anticancer Res 26(5B):3813–3817Google Scholar
  36. 36.
    Khan Z, Khan AA, Prasad G, Khan N, Tiwari RP, Bisen PS (2016) Growth inhibition and chemo-radiosensitization of head and neck squamous cell carcinoma (HNSCC) by survivin-siRNA lentivirus. Radiother Oncol 118(2):359–368CrossRefGoogle Scholar
  37. 37.
    Sobin LH, Fleming ID (1997) TNM classification of malignant tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 80(9):1803–1804CrossRefGoogle Scholar
  38. 38.
    Zhang L, Zhang W, Wang Y-F, Liu B, Zhang WF, Zhao YF, Kulkarni AB, Sun ZJ (2015) Dual induction of apoptotic and autophagic cell death by targeting survivin in head and neck squamous cell carcinoma. Cell Death Dis 6:e1771CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Adrian Münscher
    • 1
    Email author
  • Sebastian Prochnow
    • 1
  • Amit Gulati
    • 2
  • Guido Sauter
    • 3
  • Balazs Lörincz
    • 4
  • Marco Blessmann
    • 5
  • Henning Hanken
    • 6
  • Arne Böttcher
    • 1
  • Till Sebastian Clauditz
    • 3
  1. 1.Department of Otolaryngology, Head and Neck SurgeryUniversity Medical Center Hamburg-EppendorfHamburgGermany
  2. 2.Department of Medical Biometry and EpidemiologyUniversity Medical Center Hamburg-EppendorfHamburgGermany
  3. 3.Institute of PathologyUniversity Medical Center Hamburg-EppendorfHamburgGermany
  4. 4.Department of Otorhinolaryngology, Head and Neck SurgeryAsklepios Altona HospitalHamburgGermany
  5. 5.Department of Plastic, Reconstructive and Aesthetic SurgeryUniversity Medical Center Hamburg-EppendorfHamburgGermany
  6. 6.Department of Oral and Maxillofacial SurgeryUniversity Medical Center Hamburg-EppendorfHamburgGermany

Personalised recommendations